

SUMMARY: EU4Health – 2023 work programme

This annex provides a summary of Annex I¹, which sets out priorities and actions, including the allocation of resources, for the implementation in 2023 of the EU4Health Programme as established under Regulation (EU) 2021/522 of the European Parliament and of the Council² ('the EU4Health Regulation').

The overall budgetary envelope for 2023 amounts to **EUR 735 788 071**³ of which EUR 428 260 000 will be grants, EUR 176 428 071 will be procurement (both under direct management) and EUR 131 100 000 will be under indirect management.

The EU4Health Programme represents an unprecedented level of financial commitment for the Union in the area of health in comparison with the previous health programmes.

The general objectives and specific objectives of the EU4Health Programme are laid down in Articles 3 and 4 of Regulation (EU) 2021/522 and are implemented based on the **strands** and **areas of actions** set out in the table below:

STRANDS & AREAS OF ACTION	2023 budget (in million EUR)
1. CRISIS PREPAREDNESS	358.40
HERA ⁴	242.75
IMPROVING AND STRENGTHENING NATIONAL SURVEILLANCE SYSTEMS	97.6
STRENGTHENING THE EU EARLY WARNING AND RESPONSE SYSTEM AND NATIONAL ALERT AND INFORMATION SYSTEMS (EWRS) ⁵	2.0
EUROPEAN IMMUNIZATION AGENDA ⁶	2.0
SUPPORT THE SET-UP AND OPERATION OF EU REFERENCE LABORATORIES	8.2
ADVISORY COMMITTEE SET-UP TO DEAL WITH EMERGENCIES	0.45
RISK ASSESSMENTS FOR CHEMICAL, ENVIRONMENTAL AND CLIMATE THREATS DRAWN UP WITHIN AGENCIES ⁷	0.6
INTEGRATED SURVEILLANCE SYSTEMS ON ANTIMICROBIAL RESISTANCE AND ANTIMICROBIAL USE	0.5
CRISIS PREPAREDNESS IN UKRAINE AND NEIGHBOURING COUNTRIES ⁸	4.3

¹ Accessible at https://ec.europa.eu/health/funding/programme_en (English only).

² Regulation (EU) 2021/522 of the European Parliament and of the Council of 24 March 2021 establishing a Programme for the Union's action in the field of health ('EU4Health Programme') for the period 2021-2027, and repealing Regulation (EU) No 282/2014 (OJ L 107, 26.3.2021, p. 1).

³ The amount includes the EFTA contributions.

⁴ Including contribution agreements with the WHO and the EIB.

⁵ Contribution agreement with the ECDC.

⁶ Contribution agreement with the WHO.

⁷ Contribution agreement with the Union agencies.

⁸ Contribution agreement with the WHO.

2. HEALTH PROMOTION & DISEASE PREVENTION	33.54
TOBACCO CONTROL POLICIES	4.0
PREVENTION OF NON-COMMUNICABLE DISEASES (NCDs) – CHRONIC RESPIRATORY DISEASES, MENTAL HEALTH, DEMENTIA	18.36
OPERATING GRANTS	9.0
SUPPORT TO HEALTH POLICY PLATFORM, SCIENTIFIC COMMITTEES, AND EXPERT GROUPS, AND SUPPORT TO EUROPEAN CLIMATE AND HEALTH OBSERVATORY	2.18
3. CANCER	187.3
CANCER PREVENTION	1.5
EU NETWORK OF COMPREHENSIVE CANCER INFRASTRUCTURES	130.5
MENTAL HEALTH AND CANCER	10.0
IMPLEMENTATION OF CANCER SCREENING PROGRAMMES	38.5
QUALITY OF LIFE OF CANCER SURVIVORS	1.5
REDUCING CANCER INEQUALITIES ⁹	2.5
IMPLEMENTATION OF STRATEGIC AGENDA FOR MEDICAL IONISING RADIATION	2.8
4. HEALTH SYSTEMS & HEALTHCARE WORKFORCE	118.42
REFORMING AND STRENGTHENING HEALTH SYSTEMS ¹⁰	8.7
ENHANCING EUROPEAN REFERENCE NETWORKS (ERNs)	83.4
STRENGTHENING THE IMPLEMENTATION OF THE LEGISLATION ON BLOOD, TISSUES AND CELLS AND ORGANS	1.4
IMPLEMENTATION OF REGULATIONS ON MEDICAL DEVICES AND IN VITRO DIAGNOSTIC MEDICAL DEVICES	8.25
IMPLEMENTATION OF PHARMACEUTICALS LEGISLATION AND PHARMACEUTICAL STRATEGY FOR EUROPE ¹¹	8.17
IMPLEMENTATION OF THE HEALTH TECHNOLOGY ASSESSMENT REGULATION	3.00
IMPLEMENTATION OF THE CROSS-BORDER HEALTHCARE DIRECTIVE	0.5
GLOBAL HEALTH	5.0
5. DIGITAL	26.0
EUROPEAN HEALTH DATA SPACE – INFRASTRUCTURE AND GOVERNANCE, PRIMARY USE OF DATA	19.5

⁹ Contribution agreement with the OECD.

¹⁰ Including contribution agreements with the OECD, the WHO and the IOM.

¹¹ Including contribution agreements with the OECD and the Council of Europe /EDQM.

EUROPEAN HEALTH DATA SPACE – INFRASTRUCTURE AND GOVERNANCE, SECONDARY USE OF DATA	6.5
6. OTHER ACTIONS	12.12
COMMUNICATION ACTIVITIES	3.67
RECURRENT IT ACTIVITIES	5.5
OTHER ACTIVITIES	2.95

The **actions proposed for funding** are set out in the bullet points below, and cover five main areas: (i) action grants; (ii) procurement under direct management; (iii) IT support; (iv) other; and (v) actions under indirect management.

Action grants

Call for proposals to support:

- a) access to medical devices for cross-border health threats (HERA);
- b) prevention of NCDs in the area of chronic respiratory diseases;
- c) prevention of NCDs: mental health actions in particular to support vulnerable population groups (migrants, refugees, Roma people and displaced people from Ukraine);
- d) mental health challenges for cancer patients and survivors;
- e) prevention of NCDs in the area of dementia and other neurological disorders;
- f) implementation of the strategic agenda for medical ionising radiation applications: organisation of clinical audit campaigns;
- g) safety and quality of new substances of human origin (breast milk, faecal microbiota transplants);
- h) facilitating organ paired exchange;
- i) orphan medical devices, in particular targeting paediatric patients.

Grants for actions co-financed with Member States' authorities / joint actions:

- a) improving and strengthening national surveillance systems;
- b) implementation of cancer screening programmes;
- c) establishing EU network of comprehensive cancer infrastructures and new networks of expertise on cancers and cancer conditions;
- d) enhancing, extending and consolidating wastewater surveillance for public health (HERA);
- e) the Healthier Together' EU NCD initiative, focusing on chronic respiratory diseases, mental health, dementia and other neurological disorders;
- f) implementation of the strategic agenda for medical ionising radiation applications;
- g) global health;
- h) increasing the semantic interoperability of health data and building national capacity on health terminologies;
- i) development and enhancement of MyHealth@EU services, including vaccination card services;
- j) preparatory actions for the reuse of data in the proposed European Health Data Space.

Other direct grants :

- a) support to the set-up and operation of the EU reference laboratories for the Diagnostics of Human Pathogens Network (II);
- b) support to the coordination, management, and operational activities of the European Reference Networks (ERNs);
- c) support to the EU reference laboratories for the Union contribution on in-vitro diagnostic medical devices;
- d) support to the Africa Pathogen Genomics Initiative (Africa PGI) (HERA).

Procurement under direct management:

- a) support to speed up the development of, access to and/or uptake of innovative technologies and critical medicines (HERA);
- b) support to the Commission on identifying priority threats and medical countermeasures (HERA);
- c) support to existing wastewater activities including an EU sentinel system (HERA);
- d) support to epidemic intelligence from open sources (HERA);
- e) support to the innovation and access to antimicrobials (HERA);
- f) purchase of medical countermeasures in emergency situations (HERA);
- g) table-top exercise on cross-border health emergencies (HERA);
- h) gap analysis on knowledge and skills (HERA);
- i) training on management of medical countermeasures: public procurement in times of crisis (HERA);
- j) support to the set-up and operation of the EU reference laboratories for the Diagnostics of Human Pathogens Network (I);
- k) the setting up of an advisory committee (ad-hoc operation in case of emergencies);
- l) feasibility study on integrated surveillance systems on Antimicrobial resistance and antimicrobial use;
- m) tobacco control policy, implementation and modernisation of tobacco-control legislation;
- n) special Eurobarometer on attitudes of Europeans towards tobacco and related products;
- o) the Tobacco Products Directive - Characterising flavours: operation of technical group;
- p) technical implementation of the Tobacco Products Directive;
- q) development of EU guidelines and quality assurance schemes for lung, prostate and gastric cancer screening;
- r) an evaluation study on the use of sunbeds and cancer risk;
- s) support the implementation of the strategic agenda for medical ionising radiation applications;
- t) special Eurobarometer on attitudes of Europeans towards health warnings on alcoholic beverages;
- u) a study on the quality of life of cancer survivors;
- v) a study on the role of healthcare in reducing poverty;
- w) business continuity of the IT systems of the ERNs;
- x) implementation of the Cross-Border Healthcare Directive 2011/24/EU and improving information to patients;
- y) capacity building to support the uptake of biosimilars in a multi-stakeholder approach;
- z) joint assessment of notified bodies;
- aa) building capacity and knowledge for the implementation of the Regulation on Health Technology Assessment (HTA);

- bb) develop and operationalise a health impact assessment methodology for EU health policies;
- cc) operations of MyHealth@EU core services;
- dd) enhance MyHealth@EU core services with scenarios supporting patients' access to their health data;
- ee) database for Electronic Health Record (EHR) systems and wellness applications compliant with European Health-Data Space (EHDS) requirements;
- ff) development, deployment and Operations of the core services of the infrastructure on secondary uses of health data (HealthData@EU);
- gg) capacity building for secondary uses of health data for the EHDS;
- hh) confidence on vaccination of general population and health professionals, about quality and safety of vaccines;
- ii) evaluation of the Regulation on serious cross-border threats to health and of the Regulation on an extended mandate of the European Centre for Disease prevention and Control.

IT support:

- a) data analytics;
- b) support to the European Medicinal Products database;
- c) Tobacco Products Directive: operation of IT databases;
- d) support to EUDAMED;
- e) ensuring the development and completion of the HTA IT platform;
- f) support to the digital passenger locator form (EUdPLF) platform.

Other: annual membership fees for international organisations and regulatory bodies and other contributions:

- a) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use;
- b) International Pharmaceutical Regulators Programme;
- c) administrative support to the National Competent Authorities on Pricing and Reimbursement;
- d) European Observatory of Health Systems and Policies;
- e) meetings of standing committees, ad-hoc meetings, committees and other events;
- f) expert evaluators;
- g) European Climate and Health Observatory;
- h) Member States' participation in the mutual-recognition agreements on monitoring/audits in the pharmaceuticals field;
- i) technical secretariat for Notified Bodies Coordination Group;
- j) technical and administrative support to the Medical Device Coordination Group;
- k) events organised by the Presidency of the Council of the European Union;
- l) technical and administrative support to the Joint Industrial Cooperation Forum;
- m) studies on the COVID-19 pandemic;
- n) contribution to the organisations of conferences and events.

Actions implemented in indirect management:

- a) European Investment Bank (EIB) – Blending under the Thematic Innovation financial product implemented by the EIB under the InvestEU Fund (HERA)

- b) WHO – European Immunization Agenda (EIA2030) Monitoring and accountability framework for high-quality data towards evidence-informed decision making;
- c) WHO – Improve intelligence gathering in Africa;
- d) EFSA, ECHA, EEA, EMCDDA, EUROPOL, EMA – Risk assessments for chemical, environmental and climate threats drawn up within agencies;
- e) ECDC – Improving and strengthening the EU early warning and response system and national alert and information systems;
- f) WHO – Ensuring public-health and crisis-response capacities in Ukraine and neighbouring countries;
- g) OECD – Cancer inequalities registry: biennial reports and index by OECD;
- h) OECD – State of Health in the EU – 5th cycle: ‘Health at a Glance 2024: Europe’, Country Health Profiles 2025 and Synthesis Report 2025;
- i) WHO (European Observatory on Health Systems and Policies) - State of Health in the EU – 5th cycle: ‘Health at a Glance 2024: Europe’, Country Health Profiles 2025 and Synthesis Report 2025;
- j) OECD – Improving the availability, accessibility and affordability of medicinal products;
- k) Council of Europe - European Directorate for the Quality of Medicines & HealthCare: Support for Pharmaceuticals;
- l) WHO – Improving access to healthcare for refugees and people displaced from Ukraine benefitting of temporary protection in Member States;
- m) IOM – Improving access to healthcare for refugees and people displaced from Ukraine benefitting of temporary protection in Member States.